In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report). The ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target increased by equities researchers at Mizuho from ...

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.

SG Americas Securities LLC decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 69.3% ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...